Researchers from Atyr Pharma Inc. presented findings from the innovative tRNA synthetase platform, highlighting ATYR-0101, a potential therapeutic biologic based on a domain appended to aspartyl-tRNA synthetase (DARS).
Hunan Warrant Pharmaceutical Technology Development Co. Ltd. has disclosed data on the identification of a novel small-molecule inhibitor of Bruton tyrosine kinase (BTK), HND-01, which was identified by modifying metabolite 20 of dasatinib and is being developed for the potential treatment of cancer.
A rare cell type in the gut, the enterochromaffin (EC) cell, drove both gut discomfort and anxiety symptoms in animal models of gastrointestinal pain. Furthermore, the cells reacted differently in male and female mice, opening up new ways to understand and investigate the higher prevalence of gut disorders in women.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 5-fluoro-7h-pyrrolo[2,3-d] pyrimidine compounds as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
Researchers from Centre National de la Recherche Scientifique, Inserm, Institut Curie and Uniwersytet im Adama Mickiewicza have prepared nitrogen-containing salinomycin derivatives reported to be useful for the treatment of cancer.
Research at Artica Therapeutics BV has led to the development of C-C chemokine receptor type 2 (CCR2B) antagonists reported to be useful for the treatment of cancer.
RSS
